Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer.

Samaranayake GJ, Troccoli CI, Huynh M, Lyles RDZ, Kage K, Win A, Lakshmanan V, Kwon D, Ban Y, Chen SX, Zarco ER, Jorda M, Burnstein KL, Rai P.

Nat Commun. 2017 Oct 31;8(1):1204. doi: 10.1038/s41467-017-01269-x.

2.

Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.

Magani F, Peacock SO, Rice MA, Martinez MJ, Greene AM, Magani PS, Lyles R, Weitz JR, Burnstein KL.

Mol Cancer Res. 2017 Nov;15(11):1469-1480. doi: 10.1158/1541-7786.MCR-17-0280. Epub 2017 Aug 15.

PMID:
28811363
3.

Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity.

Udayakumar TS, Stoyanova R, Shareef MM, Mu Z, Philip S, Burnstein KL, Pollack A.

Mol Cancer Ther. 2016 Jun;15(6):1353-63. doi: 10.1158/1535-7163.MCT-15-0332. Epub 2016 Mar 4.

4.

The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related.

Rice MA, Ishteiwy RA, Magani F, Udayakumar T, Reiner T, Yates TJ, Miller P, Perez-Stable C, Rai P, Verdun R, Dykxhoorn DM, Burnstein KL.

Oncogene. 2016 Sep 8;35(36):4752-61. doi: 10.1038/onc.2016.6. Epub 2016 Feb 22.

5.

A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells.

Fahrenholtz CD, Greene AM, Beltran PJ, Burnstein KL.

Oncotarget. 2014 Oct 15;5(19):9007-21.

6.

VAV3 mediates resistance to breast cancer endocrine therapy.

Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J, Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A, Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA.

Breast Cancer Res. 2014 May 28;16(3):R53. doi: 10.1186/bcr3664.

7.

Coactivator MYST1 regulates nuclear factor-κB and androgen receptor functions during proliferation of prostate cancer cells.

Jaganathan A, Chaurasia P, Xiao GQ, Philizaire M, Lv X, Yao S, Burnstein KL, Liu DP, Levine AC, Mujtaba S.

Mol Endocrinol. 2014 Jun;28(6):872-85. doi: 10.1210/me.2014-1055. Epub 2014 Apr 4.

8.

Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.

Fahrenholtz CD, Rick FG, Garcia MI, Zarandi M, Cai RZ, Block NL, Schally AV, Burnstein KL.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1084-9. doi: 10.1073/pnas.1323102111. Epub 2014 Jan 6.

9.

Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.

Fahrenholtz CD, Beltran PJ, Burnstein KL.

Mol Cancer Ther. 2013 Apr;12(4):394-404. doi: 10.1158/1535-7163.MCT-12-0648. Epub 2013 Jan 24.

10.

The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells.

Ishteiwy RA, Ward TM, Dykxhoorn DM, Burnstein KL.

PLoS One. 2012;7(12):e52106. doi: 10.1371/journal.pone.0052106. Epub 2012 Dec 26.

11.

Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.

Wu F, Peacock SO, Rao S, Lemmon SK, Burnstein KL.

J Biol Chem. 2013 Feb 22;288(8):5463-74. doi: 10.1074/jbc.M112.390963. Epub 2012 Dec 31.

12.

In vivo 17β-estradiol treatment contributes to podocyte actin stabilization in female db/db mice.

Catanuto P, Fornoni A, Pereira-Simon S, Wu F, Burnstein KL, Xia X, Conti F, Lenzi A, Elliot S.

Endocrinology. 2012 Dec;153(12):5888-95. doi: 10.1210/en.2012-1637. Epub 2012 Oct 15.

13.

Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.

Peacock SO, Fahrenholtz CD, Burnstein KL.

Mol Endocrinol. 2012 Dec;26(12):1967-79. doi: 10.1210/me.2012-1165. Epub 2012 Sep 28.

14.

A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer.

Rao S, Lyons LS, Fahrenholtz CD, Wu F, Farooq A, Balkan W, Burnstein KL.

Oncogene. 2012 Feb 9;31(6):716-27. doi: 10.1038/onc.2011.273. Epub 2011 Jul 18.

15.

Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer.

Rosenblatt AE, Garcia MI, Lyons L, Xie Y, Maiorino C, Désiré L, Slingerland J, Burnstein KL.

Endocr Relat Cancer. 2011 Feb 23;18(2):207-19. doi: 10.1677/ERC-10-0049. Print 2011 Apr.

16.

GADD45gamma: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells.

Flores O, Burnstein KL.

Endocrinology. 2010 Oct;151(10):4654-64. doi: 10.1210/en.2010-0434. Epub 2010 Aug 25.

17.

Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition.

Flores O, Wang Z, Knudsen KE, Burnstein KL.

Endocrinology. 2010 Mar;151(3):896-908. doi: 10.1210/en.2009-1116. Epub 2010 Feb 10.

18.

Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic.

Rosenblatt AE, Burnstein KL.

Mol Endocrinol. 2009 Mar;23(3):412-21. doi: 10.1210/me.2008-0235. Epub 2009 Jan 8.

19.

Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells.

Lee JG, Zheng R, McCafferty-Cepero JM, Burnstein KL, Nanus DM, Shen R.

Mol Carcinog. 2009 Feb;48(2):141-9. doi: 10.1002/mc.20462.

20.

Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.

Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA, Burnstein KL.

Mol Endocrinol. 2008 Mar;22(3):597-608. Epub 2007 Dec 13.

21.

International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors.

Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, Wilson EM, McDonnell DP, Cidlowski JA.

Pharmacol Rev. 2006 Dec;58(4):782-97. Review. No abstract available.

23.

Regulation of androgen receptor levels: implications for prostate cancer progression and therapy.

Burnstein KL.

J Cell Biochem. 2005 Jul 1;95(4):657-69. Review.

PMID:
15861399
24.

Androgen-induced mineralization by MC3T3-E1 osteoblastic cells reveals a critical window of hormone responsiveness.

Balkan W, Burnstein KL, Schiller PC, Perez-Stable C, D'Ippolito G, Howard GA, Roos BA.

Biochem Biophys Res Commun. 2005 Mar 18;328(3):783-9.

PMID:
15694414
25.

Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells.

Knight-Krajewski S, Welsh CF, Liu Y, Lyons LS, Faysal JM, Yang ES, Burnstein KL.

Oncogene. 2004 Jul 15;23(32):5513-22.

PMID:
15077174
26.

Hormone resistance: it's SMRT to fight repression.

Burnstein KL, Luetje CW.

Endocrinology. 2004 Apr;145(4):1525-6. No abstract available.

PMID:
15026376
27.
28.

Antiandrogenic activity of extracts of diesel exhaust particles emitted from diesel-engine truck under different engine loads and speeds.

Okamura K, Kizu R, Toriba A, Murahashi T, Mizokami A, Burnstein KL, Klinge CM, Hayakawa K.

Toxicology. 2004 Feb 15;195(2-3):243-54.

PMID:
14751679
29.

Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3.

Schwartz GG, Eads D, Rao A, Cramer SD, Willingham MC, Chen TC, Jamieson DP, Wang L, Burnstein KL, Holick MF, Koumenis C.

Carcinogenesis. 2004 Jun;25(6):1015-26. Epub 2004 Jan 23.

PMID:
14742320
30.

Antiandrogenic activities of diesel exhaust particle extracts in PC3/AR human prostate carcinoma cells.

Kizu R, Okamura K, Toriba A, Mizokami A, Burnstein KL, Klinge CM, Hayakawa K.

Toxicol Sci. 2003 Dec;76(2):299-309. Epub 2003 Sep 11.

PMID:
12970580
31.
32.

Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.

Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG.

Recent Results Cancer Res. 2003;164:273-88.

PMID:
12899529
33.

A role of aryl hydrocarbon receptor in the antiandrogenic effects of polycyclic aromatic hydrocarbons in LNCaP human prostate carcinoma cells.

Kizu R, Okamura K, Toriba A, Kakishima H, Mizokami A, Burnstein KL, Hayakawa K.

Arch Toxicol. 2003 Jun;77(6):335-43. Epub 2003 Mar 12.

PMID:
12799773
34.

25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer.

Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF, Chen TC.

J Steroid Biochem Mol Biol. 2002 Jun;81(2):135-40.

PMID:
12137802
35.

Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer.

Yang ES, Maiorino CA, Roos BA, Knight SR, Burnstein KL.

Mol Cell Endocrinol. 2002 Jan 15;186(1):69-79.

PMID:
11850123
37.

The androgen receptor (AR) amino-terminus imposes androgen-specific regulation of AR gene expression via an exonic enhancer.

Grad JM, Lyons LS, Robins DM, Burnstein KL.

Endocrinology. 2001 Mar;142(3):1107-16.

PMID:
11181525
38.

Hepatocyte growth factor and vitamin D cooperatively inhibit androgen-unresponsive prostate cancer cell lines.

Qadan LR, Perez-Stable CM, Schwall RH, Burnstein KL, Ostenson RC, Howard GA, Roos BA.

Endocrinology. 2000 Jul;141(7):2567-73.

PMID:
10875259
39.

Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase.

Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, Gao M, Burnstein KL, Nanus DM.

Endocrinology. 2000 May;141(5):1699-704.

PMID:
10803579
40.

The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.

Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF.

Clin Cancer Res. 2000 Mar;6(3):901-8.

41.
43.

Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.

Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L.

Cancer Epidemiol Biomarkers Prev. 1999 Mar;8(3):241-8.

45.

Absence of androgen-mediated transcriptional effects in osteoblastic cells despite presence of androgen receptors.

Czerwiec FS, Liaw JJ, Liu SB, Perez-Stable C, Grumbles R, Howard GA, Roos BA, Burnstein KL.

Bone. 1997 Jul;21(1):49-56.

PMID:
9213007
46.
48.

Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells.

Dai JL, Maiorino CA, Gkonos PJ, Burnstein KL.

Steroids. 1996 Sep;61(9):531-9.

PMID:
8883219
49.

Androgen and glucocorticoid regulation of androgen receptor cDNA expression.

Burnstein KL, Maiorino CA, Dai JL, Cameron DJ.

Mol Cell Endocrinol. 1995 Dec 29;115(2):177-86.

PMID:
8824893
50.

Immunocytochemical analysis of hormone mediated nuclear translocation of wild type and mutant glucocorticoid receptors.

Jewell CM, Webster JC, Burnstein KL, Sar M, Bodwell JE, Cidlowski JA.

J Steroid Biochem Mol Biol. 1995 Nov;55(2):135-46.

PMID:
7495692

Supplemental Content

Loading ...
Support Center